Saturday, August 22, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Rush to Establish Content-Authenticity Standards Amid Leadership Shakeups and Sustained Capex
Within days of each other in mid-August 2026, Google, Anthropic, and Spotify moved to formalize AI content watermarking and labeling policies, signaling an industry-wide push toward self-governed provenance standards as generative AI output floods consumer platforms. The shift coincides with executive turnover at OpenAI (Brad Lightcap's departure) and Meta's public AI manifesto, all set against continued heavy AI infrastructure capital expenditure and finance-sector moves (e.g., Wall Street paying for algorithmic edges on social signals) that underscore AI's deepening entanglement with capital markets.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,977
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,977 facts checked against source5,242 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 12, 2026

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

View original at finance.yahoo.com
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results CRISPR Therapeutics AG ZUG, Switzerland and BOSTON, Feb…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The company made meaningful advances across multiple clinical and preclinical programs including encouraging data from zugo-cel in autoimmune disease and oncology

    80% confidence

  • Company expects to provide update on CTX611 in second half of 2026

    80% confidence

  • Approximately 90% of patients in U.S. have reimbursed access to CASGEVY as of year-end 2025

    80% confidence

  • Company expects to initiate clinical trial for CTX340 in first half of 2026

    80% confidence

  • CTX321 incorporates updated guide RNA demonstrating approximately two-fold greater potency in preclinical testing compared to CTX320

    80% confidence

  • CTX611 program has potential to target multi-billion-dollar market opportunity including atrial fibrillation, venous thromboembolism, ischemic stroke, and other indications

    80% confidence

  • Patient initiations and first cell collections increased nearly three-fold in 2025 compared to 2024

    80% confidence

  • Company expects to initiate clinical trial for CTX460 in mid-2026

    80% confidence

  • Company expects to provide update on CTX310 in second half of 2026

    80% confidence

  • CRISPR Therapeutics continues to make steady progress across a broad and increasingly mature pipeline

    80% confidence

  • Global regulatory submissions for CASGEVY in children ages 5-11 expected to begin in first half of 2026

    80% confidence

  • Company expects to provide updates on zugo-cel in autoimmune disease and immuno-oncology in second half of 2026

    80% confidence

Cited in these Via News reports